ZIA SC 010373 (ZIA) | |||
---|---|---|---|
Title | The Synergy Between Radiotherapy and Molecularly Targeted Agents | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Camphausen, Kevin | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $826,126 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Chemotherapy (75.0%) Digestive Diseases (10.0%) |
Brain (65.0%) Central Nervous System - Not Including Brain (15.0%) Colon/Rectum (4.0%) Head and Neck (10.0%) Liver Cancer (4.0%) Nervous System (80.0%) Pancreas (2.0%) |
||
Research Type | |||
Localized Therapies - Discovery and Development Localized Therapies - Clinical Applications |
|||
Abstract | |||
The goal of this project is to study the interaction of radiotherapy and molecularly targeted agents. This project focuses on expanding drugs that show synergy in vitro to the in vivo setting, with the goal of translation to the clinic. This is a translational project. We begin in the laboratory testing drugs in combination with radiotherapy in vitro. Once in vitro sensitivity is confirmed then we do in vivo work with sc or ic animal models. If a drug is shown to sensitize tumor cells to radiation then we bring it to the clinic. |